For following the competition: what moved in each program, several studies read as one move.
- Sustained-Release Gemcitabine-Docetaxel NDV-01
- enfortumab vedotin
- vepugratinib
- + 1 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Urologic Neoplasms to watchlistEvery Monday by email · turn it off any timePro · free during the beta